Shares

9 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 14, 2022

SELL
$66.18 - $82.86 $1,323 - $1,657
-20 Reduced 4.14%
463 $31,000
Q2 2022

Aug 15, 2022

BUY
$66.18 - $83.18 $25,148 - $31,608
380 Added 368.93%
483 $37,000
Q3 2020

Nov 06, 2020

SELL
$85.07 - $109.69 $5,104 - $6,581
-60 Reduced 36.81%
103 $9,000
Q2 2020

Jul 15, 2020

BUY
$74.18 - $108.93 $2,299 - $3,376
31 Added 23.48%
163 $17,000
Q1 2020

May 14, 2020

BUY
$63.18 - $85.97 $8,339 - $11,348
132 New
132 $10,000
Q4 2018

Feb 04, 2019

SELL
$58.5 - $69.94 $19,597 - $23,429
-335 Closed
0 $0
Q3 2018

Nov 07, 2018

BUY
$61.75 - $74.23 $20,686 - $24,867
335 New
335 $23,000
Q2 2018

Jul 31, 2018

SELL
$60.85 - $83.98 $6,085 - $8,398
-100 Closed
0 $0
Q1 2018

May 14, 2018

BUY
$83.06 - $100.98 $8,306 - $10,098
100 New
100 $8,000

Others Institutions Holding INCY

About INCYTE CORP


  • Ticker INCY
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 222,431,008
  • Market Cap $16.1B
  • Description
  • Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...
More about INCY
Track This Portfolio

Track Howe & Rusling Inc Portfolio

Follow Howe & Rusling Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Howe & Rusling Inc, based on Form 13F filings with the SEC.

News

Stay updated on Howe & Rusling Inc with notifications on news.